R Perez-Soler

Summary

Affiliation: Montefiore Medical Center
Country: USA

Publications

  1. ncbi request reprint Tyrosine kinase inhibitors: a clinical perspective
    Sanjay Goel
    Division of Oncology, Montefiore Medical Center, 111 East 210th Street, Bronx, NY 10467, USA
    Curr Oncol Rep 4:9-19. 2002
  2. ncbi request reprint Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?
    Roman Perez-Soler
    Department of Oncology, Montefiore Medical Center, Bronx, NY, USA
    J Clin Oncol 23:5235-46. 2005
  3. doi request reprint Individualized therapy in non-small-cell lung cancer: future versus current clinical practice
    R Perez-Soler
    Division of Medical Oncology, Department of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY 10467, USA
    Oncogene 28:S38-45. 2009
  4. ncbi request reprint HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum
    Roman Perez-Soler
    Department of Oncology, Hofheimer 100, Montefiore Medical Center Albert Einstein College of Medicine, 111 East 210th Street, Bronx, New York 10467, USA
    Oncologist 10:345-56. 2005
  5. doi request reprint The phosphatase inhibitor menadione (vitamin K3) protects cells from EGFR inhibition by erlotinib and cetuximab
    Roman Perez-Soler
    Department of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York 10467, USA
    Clin Cancer Res 17:6766-77. 2011
  6. ncbi request reprint HER1/EGFR targeting: refining the strategy
    Roman Perez-Soler
    Department of Oncology, Montefiore Medical Center Albert Einstein College of Medicine, Bronx, New York 10467, USA
    Oncologist 9:58-67. 2004
  7. ncbi request reprint Erlotinib: recent clinical results and ongoing studies in non small cell lung cancer
    Roman Perez-Soler
    Department of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York 10467 2490, USA
    Clin Cancer Res 13:s4589-92. 2007
  8. ncbi request reprint Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer
    Roman Perez-Soler
    Department of Oncology, Montefiore Medical Center Albert Einstein College of Medicine, 111 E 210th St, Bronx, NY 10467, USA
    J Clin Oncol 22:3238-47. 2004
  9. ncbi request reprint Rash as a surrogate marker for efficacy of epidermal growth factor receptor inhibitors in lung cancer
    Roman Perez-Soler
    Albert Einstein College of Medicine, Bronx, NY 10467, USA
    Clin Lung Cancer 8:S7-14. 2006
  10. ncbi request reprint Phase II clinical trial data with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) in non-small-cell lung cancer
    Roman Perez-Soler
    Department of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY 10467, USA
    Clin Lung Cancer 6:S20-3. 2004

Research Grants

  1. Determinants of Resistance to Erlotinib in NSCLC
    Roman Perez Soler; Fiscal Year: 2010
  2. CATIONIC LIPID/P53 GENE THERAPY IN LUNG CANCER PATIENTS
    Roman Perez Soler; Fiscal Year: 2001
  3. Determinants of Resistance to Erlotinib in NSCLC
    Roman Perez Soler; Fiscal Year: 2009
  4. Determinants of Resistance to Erlotinib in NSCLC
    Roman Perez Soler; Fiscal Year: 2008
  5. Determinants of Resistance to Erlotinib in NSCLC
    Roman Perez Soler; Fiscal Year: 2007
  6. Determinants of Resistance to Erlotinib in NSCLC
    Roman Perez Soler; Fiscal Year: 2006
  7. Chemotherapy and anti-EGFR Antibody C225 in Lung Cancer
    Roman Perez Soler; Fiscal Year: 2004
  8. INNOVATIVE TUMOR TARGETED THERAPIES FOR LUNG CANCER
    Roman Perez Soler; Fiscal Year: 2004
  9. Chemotherapy and anti-EGFR Antibody C225 in Lung Cancer
    Roman Perez Soler; Fiscal Year: 2003
  10. CATIONIC LIPID/P53 GENE THERAPY IN LUNG CANCER PATIENTS
    Roman Perez Soler; Fiscal Year: 2003

Detail Information

Publications48

  1. ncbi request reprint Tyrosine kinase inhibitors: a clinical perspective
    Sanjay Goel
    Division of Oncology, Montefiore Medical Center, 111 East 210th Street, Bronx, NY 10467, USA
    Curr Oncol Rep 4:9-19. 2002
    ..Other uses are being tested, such as imatinib for gastrointestinal stromal tumor. These compounds will alter cancer care as adjuncts to currently available treatment options...
  2. ncbi request reprint Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?
    Roman Perez-Soler
    Department of Oncology, Montefiore Medical Center, Bronx, NY, USA
    J Clin Oncol 23:5235-46. 2005
    ..The cause of the possible relationship between rash and clinical benefit remains unclear at this time, and additional studies are needed to determine the clinical utility of this observation...
  3. doi request reprint Individualized therapy in non-small-cell lung cancer: future versus current clinical practice
    R Perez-Soler
    Division of Medical Oncology, Department of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY 10467, USA
    Oncogene 28:S38-45. 2009
    ..Although there are still significant challenges to implementing genomic and proteomic testing in clinical practice, the rapid development of newer technologies provides hope for overcoming these barriers...
  4. ncbi request reprint HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum
    Roman Perez-Soler
    Department of Oncology, Hofheimer 100, Montefiore Medical Center Albert Einstein College of Medicine, 111 East 210th Street, Bronx, New York 10467, USA
    Oncologist 10:345-56. 2005
    ..The increasing use of HER1/EGFR-targeted agents makes managing rash important. We hope the outcomes from this Forum provide background for future studies...
  5. doi request reprint The phosphatase inhibitor menadione (vitamin K3) protects cells from EGFR inhibition by erlotinib and cetuximab
    Roman Perez-Soler
    Department of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York 10467, USA
    Clin Cancer Res 17:6766-77. 2011
    ..We hypothesized that phosphatase inhibition in the skin keratinocytes may prevent receptor dephosphorylation caused by EGFR inhibitors and be used as a new potential strategy for the prevention or treatment of this side effect...
  6. ncbi request reprint HER1/EGFR targeting: refining the strategy
    Roman Perez-Soler
    Department of Oncology, Montefiore Medical Center Albert Einstein College of Medicine, Bronx, New York 10467, USA
    Oncologist 9:58-67. 2004
    ..It is important to remember that intracellular targeting of HER is a relatively novel approach, and our knowledge of how best to optimize such treatment is still unfolding. More clinical experience is needed...
  7. ncbi request reprint Erlotinib: recent clinical results and ongoing studies in non small cell lung cancer
    Roman Perez-Soler
    Department of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York 10467 2490, USA
    Clin Cancer Res 13:s4589-92. 2007
    ..Clinical studies addressing these five areas are ongoing and are briefly described in this review...
  8. ncbi request reprint Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer
    Roman Perez-Soler
    Department of Oncology, Montefiore Medical Center Albert Einstein College of Medicine, 111 E 210th St, Bronx, NY 10467, USA
    J Clin Oncol 22:3238-47. 2004
    ..This phase II study of erlotinib in patients with HER1/EGFR-expressing non-small-cell lung cancer previously treated with platinum-based chemotherapy evaluated tumor response, survival, and symptom improvement...
  9. ncbi request reprint Rash as a surrogate marker for efficacy of epidermal growth factor receptor inhibitors in lung cancer
    Roman Perez-Soler
    Albert Einstein College of Medicine, Bronx, NY 10467, USA
    Clin Lung Cancer 8:S7-14. 2006
    ....
  10. ncbi request reprint Phase II clinical trial data with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) in non-small-cell lung cancer
    Roman Perez-Soler
    Department of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY 10467, USA
    Clin Lung Cancer 6:S20-3. 2004
    ..Erlotinib is active and well tolerated in patients with NSCLC as first- and second-line therapy. Cutaneous rash appears to be a surrogate marker of clinical benefit, but this finding needs to be confirmed in ongoing and future studies...
  11. ncbi request reprint Clinical research of EGFR inhibitors and related dermatologic toxicities
    Roman Perez-Soler
    Division of Medical Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, USA
    Oncology (Williston Park) 21:10-6. 2007
    ..Rational treatments based on the biological mechanisms of the skin toxicity must be developed and tested in well-controlled clinical trials...
  12. ncbi request reprint Response and determinants of sensitivity to paclitaxel in human non-small cell lung cancer tumors heterotransplanted in nude mice
    R Perez-Soler
    Kaplan Comprehensive Cancer Center, New York University School of Medicine, New York, New York 10016, USA
    Clin Cancer Res 6:4932-8. 2000
    ..NSCLC heterotransplants deserve to be explored to evaluate new agents for lung cancer and to predict clinical response on an individual basis in selected groups of patients...
  13. ncbi request reprint Schedule-dependent interaction between the proteosome inhibitor bortezomib and the EGFR-TK inhibitor erlotinib in human non-small cell lung cancer cell lines
    Bilal Piperdi
    Division of Medical Oncology, Department of Medicine, UMASS Memorial Cancer Center, University of Massachusetts, Worcester, Massachusetts 01655, USA
    J Thorac Oncol 2:715-21. 2007
    ..We studied the combination of these two novel biologic agents in vitro using a panel of non-small cell lung cancer cell lines...
  14. doi request reprint Activation of ER stress and inhibition of EGFR N-glycosylation by tunicamycin enhances susceptibility of human non-small cell lung cancer cells to erlotinib
    Yi He Ling
    Department of Oncology, Albert Einstein College of Medicine, Bronx, NY, USA
    Cancer Chemother Pharmacol 64:539-48. 2009
    ..In this study, we examined whether inhibition of EGFR N-glycosylation and stimulation of endoplasmic reticulum (ER) stress by tunicamycin enhances erlotinib-induced growth inhibition in NSCLC cell lines...
  15. pmc PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab
    Minaxi Jhawer
    Department of Oncology, Montefiore Medical Center, Albert Einstein Cancer Center, Bronx, NY 10467, USA
    Cancer Res 68:1953-61. 2008
    ..A priori screening of colon tumors for PTEN expression status and PIK3CA and Ras/BRAF mutation status could help stratify patients likely to benefit from this therapy...
  16. ncbi request reprint Erlotinib, an effective epidermal growth factor receptor tyrosine kinase inhibitor, induces p27KIP1 up-regulation and nuclear translocation in association with cell growth inhibition and G1/S phase arrest in human non-small-cell lung cancer cell lines
    Yi He Ling
    Department of Oncology, Albert Einstein College of Medicine, Bronx, New York, USA
    Mol Pharmacol 72:248-58. 2007
    ..Taken together, these results suggest that erlotinib inhibits human NSCLC cell growth predominantly by inducing p27(KIP1) expression and by suppressing cell-cycle events involved in the G1/S transition...
  17. ncbi request reprint Erlotinib induces mitochondrial-mediated apoptosis in human H3255 non-small-cell lung cancer cells with epidermal growth factor receptorL858R mutation through mitochondrial oxidative phosphorylation-dependent activation of BAX and BAK
    Yi He Ling
    Division of Medical Oncology, Albert Einstein College of Medicine, Bronx, New York, USA
    Mol Pharmacol 74:793-806. 2008
    ..Our data indicate that activation of BAX and BAK plays a critical role in the initiation of erlotinib-induced apoptotic cascades...
  18. ncbi request reprint Enhancement of the therapeutic efficacy of taxol by the mitogen-activated protein kinase kinase inhibitor CI-1040 in nude mice bearing human heterotransplants
    Hayley M McDaid
    Department of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, New York 10461, USA
    Cancer Res 65:2854-60. 2005
    ..These findings are significant and indicate that this combination may have broad therapeutic applications in a diverse range of lung tumors with different intrinsic chemosensitivities...
  19. pmc Molecular pharmacodynamics of PM02734 (elisidepsin) as single agent and in combination with erlotinib; synergistic activity in human non-small cell lung cancer cell lines and xenograft models
    Yi He Ling
    Division of Medical Oncology, Albert Einstein College of Medicine, Bronx, New York, USA
    Eur J Cancer 45:1855-64. 2009
    ..These results have provided a rational basis for an ongoing clinical trial to explore this combination in patients with advanced malignant solid tumours...
  20. ncbi request reprint Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells
    Tianhong Li
    Department of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York 10461, USA
    Clin Cancer Res 13:3413-22. 2007
    ..This study was undertaken to select the optimal combination schedule of erlotinib and pemetrexed for the treatment of relapsed non-small cell lung cancer (NSCLC) using a panel of human NSCLC lines...
  21. ncbi request reprint Tumor dependence on the EGFR signaling pathway expressed by the p-EGFR:p-AKT ratio predicts erlotinib sensitivity in human non-small cell lung cancer (NSCLC) cells expressing wild-type EGFR gene
    Tianhong Li
    Department of Oncology, Montefiore Medical Center and the Albert Einstein Cancer Center, Bronx, NY 10461, USA
    J Thorac Oncol 3:643-7. 2008
    ....
  22. doi request reprint Skin toxicities associated with epidermal growth factor receptor inhibitors
    Tianhong Li
    Department of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY 10461, USA
    Target Oncol 4:107-19. 2009
    ..A randomized, double-blinded, placebo-controlled study has been initiated to evaluate the clinical efficacy of menadione topical cream, in the treatment or prevention of EGFR inhibitor-induced skin toxicity...
  23. doi request reprint Phase II study of the proteasome inhibitor bortezomib (PS-341, Velcade) in chemotherapy-naïve patients with advanced stage non-small cell lung cancer (NSCLC)
    Tianhong Li
    Department of Oncology, Montefiore Medical Center and the Albert Einstein College of Medicine, Bronx, NY, United States
    Lung Cancer 68:89-93. 2010
    ..Grade 3 toxicities included fatigue (N=1, 8%), deep vein thrombosis (N=1, 8%) and thrombocytopenia (N=1, 8%). Although well tolerated, bortezomib monotherapy is not active in this cohort of chemotherapy-naïve, metastatic NSCLC...
  24. ncbi request reprint EGFR inhibitor-mediated apoptosis in solid tumors
    Sanjay Goel
    Montefiore Medical Center and Albert Einstein College of Medicine 1825 Eastchester Road, Bronx, NY 10461, USA
    J Exp Ther Oncol 6:305-20. 2007
    ..Further study of EGFR-modulated apoptotic pathways may facilitate the rational development of improved combination regimens...
  25. ncbi request reprint Targeting protein translation in human non small cell lung cancer via combined MEK and mammalian target of rapamycin suppression
    Marie Emmanuelle Legrier
    Department of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, New York 10461, USA
    Cancer Res 67:11300-8. 2007
    ..These data (a) provide evidence that both pathways converge on factors that regulate translation initiation and (b) support therapeutic strategies in lung cancer that simultaneously suppress the RAS and AKT signaling network...
  26. ncbi request reprint The role of erlotinib (Tarceva, OSI 774) in the treatment of non-small cell lung cancer
    Roman Perez-Soler
    Gutman Professor of Oncology, Montefiore Medical Center Albert Einstein College of Medicine, Bronx, New York, USA
    Clin Cancer Res 10:4238s-4240s. 2004
    ....
  27. ncbi request reprint Erlotinib (Tarceva): a promising drug targeting epidermal growth factor receptor tyrosine kinase
    Anca M Bulgaru
    Montefiore Medical Center, Department of Oncology, Bronx, NY 10467, USA
    Expert Rev Anticancer Ther 3:269-79. 2003
    ..This drug has demonstrated promising antitumor activity in Phase II trials in several solid tumors and definitive Phase III studies to demonstrate clinical benefit have completed accrual...
  28. ncbi request reprint Disruption of cell adhesion and caspase-mediated proteolysis of beta- and gamma-catenins and APC protein in paclitaxel-induced apoptosis
    Y Ling
    Kaplan Comprehensive Cancer Center, New York University School of Medicine, New York, New York, USA
    Mol Pharmacol 59:593-603. 2001
    ..All our data demonstrate that the caspase-mediated cleavage of beta-catenin, gamma-catenin, and APC protein might contribute to paclitaxel-induced apoptosis...
  29. ncbi request reprint Complex effects of Ras proto-oncogenes in tumorigenesis
    Roberto Diaz
    Department of Pathology and NYU Cancer Institute, New York University School of Medicine, New York, NY 10016, USA
    Carcinogenesis 25:535-9. 2004
    ..Considered together, our results indicate that Ras proto-oncogenes can enhance or inhibit the malignant phenotype in vivo in different systems...
  30. ncbi request reprint Loss of H-cadherin protein expression in human non-small cell lung cancer is associated with tumorigenicity
    Y Zhong
    Kaplan Comprehensive Cancer Center, New York University School of Medicine, New York, New York 10016, USA
    Clin Cancer Res 7:1683-7. 2001
    ..The results indicate that loss of H-cadherin is frequent in human NSCLC and suggest that it facilitates the implantation and local growth of human NSCLC tumors...
  31. ncbi request reprint p53 aerosol formulation with low toxicity and high efficiency for early lung cancer treatment
    Yiyu Zou
    Department of Medicine, Albert Einstein College of Medicine, Bronx, New York 10461, USA
    Clin Cancer Res 13:4900-8. 2007
    ..To develop an optimal nonviral aerosol formulation for locoregional treatment of early lung cancer...
  32. ncbi request reprint Arsenic trioxide produces polymerization of microtubules and mitotic arrest before apoptosis in human tumor cell lines
    Yi He Ling
    Department of Medicine, Albert Einstein College of Medicine, Bronx, New York 10461, USA
    Mol Pharmacol 62:529-38. 2002
    ....
  33. ncbi request reprint The BCL2-family of protein ligands as cancer drugs: the next generation of therapeutics
    WenJing Liu
    Albert Einstein Comprehensive Cancer Center, Albert Einstein College of Medicine, Bronx, NY 10461, USA
    Curr Med Chem Anticancer Agents 3:217-23. 2003
    ..This rationale becomes even more striking when one observes overexpression of Bcl2 in 70% of breast cancer, 30-60% of prostate cancer, 80% of B-cell lymphomas, 90% of colorectal adenocarcinomas, and many other forms of cancer...
  34. ncbi request reprint Clinical presentation and pathophysiology of EGFRI dermatologic toxicities
    Edith P Mitchell
    Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania, USA
    Oncology (Williston Park) 21:4-9. 2007
    ..Most management strategies for these toxicities have been based on anecdotal experience; clinical trials are needed to provide uniform characterization to allow for evidence-based treatment strategies...
  35. ncbi request reprint Double blockade of cell cycle at g(1)-s transition and m phase by 3-iodoacetamido benzoyl ethyl ester, a new type of tubulin ligand
    Jian Dong Jiang
    Division of Medical Oncology, Mount Sinai School of Medicine New York University, New York 10029, USA
    Cancer Res 62:6080-8. 2002
    ..Besides being a novel lead for the design of new anticancer tubulin ligands, the activity of 3-IAABE in the cell cycle may also help us to understand the molecular pharmacology of microtubule-active drugs...
  36. ncbi request reprint Enhanced sensitivity to the HER1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib hydrochloride in chemotherapy-resistant tumor cell lines
    Qun Dai
    Department of Oncology, Montefiore Medical Center Albert Einstein College of Medicine, 11 East 210th Street, Bronx, NY 10467, USA
    Clin Cancer Res 11:1572-8. 2005
    ..We hypothesized that some tumors treated with multiple cytotoxic therapies may become more dependent on the HER1/EGFR signaling pathways for survival...
  37. ncbi request reprint A review of small-molecule epidermal growth factor receptor-specific tyrosine kinase inhibitors in development for non-small cell lung cancer
    Katrina Y Glover
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Semin Oncol 31:83-92. 2004
    ..This article will review several of these agents as well as their role in the treatment of non-small cell lung cancer...
  38. ncbi request reprint Novel agents in the treatment of lung cancer: conference summary statement
    Thomas J Lynch
    Division of Hematology Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA
    Clin Cancer Res 10:4199s-4204s. 2004
  39. ncbi request reprint Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells
    Yi He Ling
    Department of Oncology, Albert Einstein College of Medicine, Bronx, New York 10461, USA New York University Cancer Institute, School of Medicine, New York University, New York, New York 10016, USA
    J Biol Chem 278:33714-23. 2003
    ..Thus ROS generation plays a critical role in the initiation of the bortezomib-induced apoptotic cascade by mediation of the disruption of Delta psi m and the release of cytochrome c from mitochondria...
  40. ncbi request reprint The N-ras proto-oncogene can suppress the malignant phenotype in the presence or absence of its oncogene
    Roberto Diaz
    Department of Pathology and Kaplan Comprehensive Cancer Center, New York University Medical Center, New York, New York 10016, USA
    Cancer Res 62:4514-8. 2002
    ..Taken together, our results indicate that wild-type N-ras has "tumor suppressor" activity, even in the absence of its oncogenic allele...
  41. ncbi request reprint PS-341, a novel proteasome inhibitor, induces Bcl-2 phosphorylation and cleavage in association with G2-M phase arrest and apoptosis
    Yi He Ling
    Department of Oncology, Albert Einstein College of Medicine, Bronx, New York 10461, USA
    Mol Cancer Ther 1:841-9. 2002
    ....
  42. ncbi request reprint Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines
    Yi He Ling
    Department of Oncology, Albert Einstein College of Medicine, 13200 Morris Park Avenue, Bronx, NY 10461, USA
    Clin Cancer Res 9:1145-54. 2003
    ..PS-341 is a novel dipeptide boronic acid proteasome inhibitor with in vitro and in vivo antitumor activity that induces mechanisms of apoptosis by unknown mechanisms...
  43. ncbi request reprint Phase I study of aerosolized SLIT cisplatin in the treatment of patients with carcinoma of the lung
    Bart P H Wittgen
    Department of Pulmonary Diseases, VU University Medical Center, Amsterdam, The Netherlands
    Clin Cancer Res 13:2414-21. 2007
    ..To investigate the safety and pharmacokinetics of aerosolized Sustained Release Lipid Inhalation Targeting (SLIT) Cisplatin in patients with lung carcinoma...
  44. pmc The novel highly lipophilic topoisomerase I inhibitor DB67 is effective in the treatment of liver metastases of murine CT-26 colon carcinoma
    Lluis A Lopez-Barcons
    Department of Medicine and Molecular Pharmacology, Albert Einstein Cancer Center, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461, USA
    Neoplasia 6:457-67. 2004
    ..DB67 and liposomal DB67 are more effective than irinotecan in the treatment of liver metastases after resection of the primary tumor...
  45. ncbi request reprint Altered expression of p27 and Skp2 proteins in prostate cancer of African-American patients
    Marija Drobnjak
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Clin Cancer Res 9:2613-9. 2003
    ..The abundance of p27, an inhibitor of cell proliferation, is controlled by Skp2-dependent proteolysis...
  46. ncbi request reprint Novel agents in the treatment of lung cancer: Fourth Cambridge Conference
    Thomas J Lynch
    Division of Hematology Oncology, Massachusetts General Hospital, 55 Fruit Street, Yawkey, 7th Floor, Suite 7601, Boston, MA 02114, USA
    Clin Cancer Res 13:s4583-8. 2007
    ....
  47. ncbi request reprint Role of endogenous thrombin in tumor implantation, seeding, and spontaneous metastasis
    Liang Hu
    Department of Medicine, Kaplan Cancer Center, New York University School of Medicine, NY 10016, USA
    Blood 104:2746-51. 2004
    ..Thus, endogenous thrombin contributes to tumor implantation, seeding, and spontaneous metastasis. A potent antithrombin agent should be of clinical benefit to patients with cancer...
  48. ncbi request reprint Chemopreventive therapeutics. Inhalation therapies for lung cancer and bronchial premalignancy
    Missak Haigentz
    Division of Medical Oncology, Albert Einstein College of Medicine Montefiore Medical Center, Bronx, NY, USA
    Methods Mol Med 75:771-80. 2003
    ....

Research Grants14

  1. Determinants of Resistance to Erlotinib in NSCLC
    Roman Perez Soler; Fiscal Year: 2010
    ..To confirm the predictive value of the algorithm in a group of patients with chemoresistant NSCLC selected for their high probability of achieving a response or stable disease with single agent erlotinib therapy. ..
  2. CATIONIC LIPID/P53 GENE THERAPY IN LUNG CANCER PATIENTS
    Roman Perez Soler; Fiscal Year: 2001
    ..The results of this study will provide initial but very valuable information on the potential use of this new strategy in the treatment of bronchial premalignancy, carcinoma in situ, and endobronchial lung tumors. ..
  3. Determinants of Resistance to Erlotinib in NSCLC
    Roman Perez Soler; Fiscal Year: 2009
    ..To confirm the predictive value of the algorithm in a group of patients with chemoresistant NSCLC selected for their high probability of achieving a response or stable disease with single agent erlotinib therapy. ..
  4. Determinants of Resistance to Erlotinib in NSCLC
    Roman Perez Soler; Fiscal Year: 2008
    ..To confirm the predictive value of the algorithm in a group of patients with chemoresistant NSCLC selected for their high probability of achieving a response or stable disease with single agent erlotinib therapy. ..
  5. Determinants of Resistance to Erlotinib in NSCLC
    Roman Perez Soler; Fiscal Year: 2007
    ..unreadable] [unreadable]..
  6. Determinants of Resistance to Erlotinib in NSCLC
    Roman Perez Soler; Fiscal Year: 2006
    ..unreadable] [unreadable]..
  7. Chemotherapy and anti-EGFR Antibody C225 in Lung Cancer
    Roman Perez Soler; Fiscal Year: 2004
    ..abstract_text> ..
  8. INNOVATIVE TUMOR TARGETED THERAPIES FOR LUNG CANCER
    Roman Perez Soler; Fiscal Year: 2004
    ..Four such candidates have already been identified. It is anticipated that a total of ten young clinical investigators will be mentored during a five-year period. ..
  9. Chemotherapy and anti-EGFR Antibody C225 in Lung Cancer
    Roman Perez Soler; Fiscal Year: 2003
    ..abstract_text> ..
  10. CATIONIC LIPID/P53 GENE THERAPY IN LUNG CANCER PATIENTS
    Roman Perez Soler; Fiscal Year: 2003
    ..The results of this study will provide initial but very valuable information on the potential use of this new strategy in the treatment of bronchial premalignancy, carcinoma in situ, and endobronchial lung tumors. ..
  11. Chemotherapy and anti-EGFR Antibody C225 in Lung Cancer
    Roman Perez Soler; Fiscal Year: 2002
    ..abstract_text> ..
  12. Long-Circulating Liposomal Camptothecins CAP and EAP
    Roman Perez Soler; Fiscal Year: 2003
    ..Ultimately, we will seek formulation(s) that display optimized drug retention and in vivo and in vitro performance. PROPOSED COMMERCIAL APPLICATION: Not Available ..
  13. CATIONIC LIPID/P53 GENE THERAPY IN LUNG CANCER PATIENTS
    Roman Perez Soler; Fiscal Year: 2002
    ..The results of this study will provide initial but very valuable information on the potential use of this new strategy in the treatment of bronchial premalignancy, carcinoma in situ, and endobronchial lung tumors. ..
  14. Chemotherapy and anti EGFR Antibody C225 in Lung Cancer
    Roman Perez Soler; Fiscal Year: 2001
    ..abstract_text> ..